USA - NASDAQ:IART - US4579852082 - Common Stock
The current stock price of IART is 12.33 USD. In the past month the price decreased by -14.37%. In the past year, price decreased by -46.11%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.45 | 221.04B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.45 | 205.11B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.75 | 151.88B | ||
| SYK | STRYKER CORP | 27.62 | 139.05B | ||
| IDXX | IDEXX LABORATORIES INC | 56.5 | 57.00B | ||
| BDX | BECTON DICKINSON AND CO | 13.11 | 54.18B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.14 | 50.00B | ||
| RMD | RESMED INC | 25.5 | 36.84B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.99 | 33.52B | ||
| PODD | INSULET CORP | 71.4 | 22.97B | ||
| DXCM | DEXCOM INC | 31.25 | 22.80B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.94 | 17.53B |
Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. The company is headquartered in Princeton, New Jersey and currently employs 4,396 full-time employees. The firm manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The company provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, plastics and surgical reconstruction products, and others.
INTEGRA LIFESCIENCES HOLDING
1100 Campus Road
Princeton NEW JERSEY 08540 US
CEO: Peter J. Arduini
Employees: 4396
Phone: 16092750500
Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. The company is headquartered in Princeton, New Jersey and currently employs 4,396 full-time employees. The firm manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The company provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, plastics and surgical reconstruction products, and others.
The current stock price of IART is 12.33 USD. The price increased by 1.23% in the last trading session.
IART does not pay a dividend.
IART has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
INTEGRA LIFESCIENCES HOLDING (IART) currently has 4396 employees.
INTEGRA LIFESCIENCES HOLDING (IART) has a market capitalization of 960.63M USD. This makes IART a Small Cap stock.
INTEGRA LIFESCIENCES HOLDING (IART) will report earnings on 2026-02-23, after the market close.
ChartMill assigns a fundamental rating of 4 / 10 to IART. IART has a medium profitability rating, but doesn't score so well on its financial health evaluation.
Over the last trailing twelve months IART reported a non-GAAP Earnings per Share(EPS) of 2.37. The EPS decreased by -4.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.58% | ||
| ROE | -47.74% | ||
| Debt/Equity | 1.73 |
17 analysts have analysed IART and the average price target is 17.34 USD. This implies a price increase of 40.63% is expected in the next year compared to the current price of 12.33.
For the next year, analysts expect an EPS growth of -12.37% and a revenue growth 1.34% for IART